STOCK TITAN

HCAT Form 144 Filed for 2,613 Restricted Shares Sale on 09/02/2025

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Health Catalyst, Inc. (HCAT) filing of Form 144 notifies the market that 2,613 shares of common stock will be offered for sale through Morgan Stanley Smith Barney on 09/02/2025. The filing lists an aggregate market value of $8,786.74 for the shares based on the transaction and shows 70,373,625 shares outstanding for the issuer.

The shares were acquired the same day, 09/02/2025, as restricted stock from Health Catalyst and are identified as compensation. The filer discloses a prior restricted-stock sale of 2,712 shares on 06/02/2025 yielding gross proceeds of $9,857.58. By signing, the person attests they are unaware of undisclosed material adverse information about the issuer.

Positive

  • Complete Rule 144 disclosure including broker, share count, market value, acquisition details, and prior sales
  • Attestation present that the filer does not possess undisclosed material adverse information
  • Transaction tied to compensation, and acquisition date is explicitly stated as 09/02/2025

Negative

  • None.

Insights

TL;DR: This Form 144 is a routine insider sale notice disclosing a small compensation-related sale of 2,613 shares.

The filing contains standard Rule 144 disclosure: broker details (Morgan Stanley Smith Barney), number of shares (2,613), aggregate market value ($8,786.74), and outstanding share count (70,373,625). The securities were acquired as restricted stock on the sale date and were paid as compensation, which indicates these are proceeds from an insider compensation event rather than a market purchase. The filing also lists a recent prior restricted-stock sale of 2,712 shares on 06/02/2025 for $9,857.58, which provides context on recent insider liquidity. No earnings, material contracts, or regulatory issues are disclosed here.

TL;DR: Disclosure appears complete for a Rule 144 notice; signature attestation confirms no undisclosed material information.

The document includes required information: relationship to issuer (implicit through compensation), acquisition date and nature (restricted stock), nature of payment (compensation), broker, and planned sale date. The signer affirms absence of material nonpublic information in the issuer, a standard legal attestation. The filing does not include any governance changes, insider departures, or other corporate actions.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed for Health Catalyst (HCAT) report?

The form reports an intended sale of 2,613 common shares through Morgan Stanley Smith Barney on 09/02/2025 with an aggregate market value of $8,786.74.

How were the 2,613 shares acquired by the filer?

The shares were acquired on 09/02/2025 as restricted stock from Health Catalyst and were granted as compensation.

Has the filer sold other Health Catalyst shares recently?

Yes. The filing discloses a prior sale of 2,712 restricted shares on 06/02/2025 for gross proceeds of $9,857.58.

What broker will handle the sale listed in the Form 144?

The broker named is Morgan Stanley Smith Barney LLC, located at 1 New York Plaza, 38th Floor, New York, NY 10004.

Does the filing indicate any undisclosed material information about Health Catalyst?

No. The signer expressly represents that they do not know of any material adverse information about the issuer that has not been publicly disclosed.